[{"orgOrder":0,"company":"Sydnexis","sponsor":"Visionary Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Series B Financing","leadProduct":"Atropine Sulfate","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Sydnexis","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Eye Drop","sponsorNew":"Sydnexis \/ Visionary Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Sydnexis \/ Visionary Ventures"},{"orgOrder":0,"company":"Sydnexis","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Atropine Sulfate","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Sydnexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Sydnexis \/ Santen Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sydnexis \/ Santen Pharmaceutical"}]

Find Clinical Drug Pipeline Developments & Deals by Sydnexis

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : SYD-101 is designed to be a best-in-class product with maximum efficacy, comfort and 3-year stability at room temperature, all important product attributes when developing drugs for use in children.

                          Brand Name : SYD-101

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 10, 2021

                          Lead Product(s) : Atropine Sulfate

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Visionary Ventures

                          Deal Size : $45.0 million

                          Deal Type : Series B Financing

                          blank

                          02

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The agreement aims for SYD-101, Sydnexis’ investigational proprietary low dose atropine sulfate formulation, for Europe, Middle East and Africa (EMEA), is currently undergoing a phase III clinical trial, the STAAR study, in Europe and the US to help co...

                          Brand Name : SYD-101

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 10, 2021

                          Lead Product(s) : Atropine Sulfate

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Santen Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank